Taysha Gene Therapies, Inc. (TSHA) Stock Price & Analysis
Taysha Gene Therapies, Inc. (TSHA) fell 1.29% to USD 5.36 as of June 10, 2026 at 01:00 UTC, according to Nexqual real-time market data.
TSHA last closed at USD 5.43; the session ranged USD 5.26–5.71 on volume of 3,307,815 shares. Market capitalization is $1.54B, with a 52-week range of USD 2.25–7.3 (NMS). Source: Nexqual, June 10, 2026 at 01:00 UTC.
Key Statistics (as of June 10, 2026 at 01:00 UTC)
| Price | USD 5.36 |
|---|---|
| Change | ▼ 1.29% (down) |
| Previous Close | USD 5.43 |
| Open | USD 5.51 |
| Day Range | USD 5.26 – 5.71 |
| 52-Week Range | USD 2.25 – 7.3 |
| Volume | 3,307,815 shares |
| Market Cap | $1.54B |
| Exchange | NMS |
Technical Analysis (TSHA)
Nexqual's technical model rates TSHA "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 01:00 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 37.8 (neutral) |
| vs SMA50 | Below (USD 5.76) |
| MACD | -0.12 (negative) |
Analyst Ratings (TSHA)
Wall Street analysts rate TSHA "Strong Buy" based on 13 analysts, with a mean price target of USD 12.23 (range USD 8–19), per Nexqual as of June 10, 2026 at 01:00 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 13 |
| Mean Target | USD 12.23 |
| High Target | USD 19 |
| Low Target | USD 8 |
| Buy / Hold / Sell | 13 / 0 / 0 |
Earnings (TSHA)
| Next Earnings Date | 2026-05-06 |
|---|---|
| EPS Estimate | USD -0.11 |
| Revenue Estimate | $566,670 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.11 vs est -0.1 ▼ miss |
| 2025-12-31 | USD -0.07 vs est -0.1 ▲ beat |
| 2025-09-30 | USD -0.09 vs est -0.09 ▲ beat |
| 2025-06-30 | USD -0.08 vs est -0.08 ▼ miss |
Source: Nexqual, June 10, 2026 at 01:00 UTC.
Financials & Fundamentals (TSHA)
| Total Revenue | $7.47M |
|---|---|
| Gross Margin | +100.00% |
| Operating Margin | -1774.37% |
| Profit Margin | +0.00% |
| ROE | -97.28% |
| Debt / Equity | 32.34 |
| Current Ratio | 14.04 |
| Total Cash | $276.58M |
| Total Debt | $68.55M |
| Free Cash Flow | $-73.45M |
Source: Nexqual, June 10, 2026 at 01:00 UTC.
Financial Health Score (TSHA)
Nexqual rates Taysha Gene Therapies, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 01:00 UTC.
| Growth | Strong — Revenue +17% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $277M cash vs $69M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$73M, burning cash |
| Efficiency | Critical — ROE -97%, ROA -37.8% |
Ownership (TSHA)
| Insider Ownership | +10.65% |
|---|---|
| Institutional Ownership | +95.75% |
| Shares Outstanding | 287.36M |
| Float | 196.74M |
| Short % of Float | +13.00% |
Source: Nexqual, June 10, 2026 at 01:00 UTC.
Leadership (TSHA)
Taysha Gene Therapies, Inc. is led by Sean P. Nolan (age 57), CEO & Chairman, per Nexqual as of June 10, 2026 at 01:00 UTC.
| CEO & Chairman | Sean P. Nolan (age 57) |
|---|---|
| President, Head of Research & Development and Director | Sukumar Nagendran (age 58) |
| CFO & Corporate Secretary | Kamran Alam (age 47) |
| Director of Corporate Communications & Investor Relations | Hayleigh Collins |
| Chief Scientific Advisor of UT Southwestern Gene Therapy Program | Steven Gray |
Major Backers & Investors (TSHA)
Notable institutional backers of Taysha Gene Therapies, Inc. include RA Capital Management, L.P., Goldman Sachs, Avoro Capital Advisors LLC, according to Nexqual as of June 10, 2026 at 01:00 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RA Capital Management, L.P. | 8.2% |
| Goldman Sachs | 7.78% |
| Avoro Capital Advisors LLC | 7.55% |
| Vestal Point Capital, LP | 6.26% |
| Morgan Stanley | 6.25% |
| FMR, LLC | 4.98% |
| RTW Investments LP | 4.76% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.41% |
| Vanguard Group | 7.03% |
| State Street | 6.07% |
Source: Nexqual, June 10, 2026 at 01:00 UTC.
From Taysha Gene Therapies, Inc.'s Latest SEC 10-K Filing (filed 2026-03-19)
Key Strengths & Strategy (as disclosed to the SEC)
- Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system.
- The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome.
- The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CCCC | C4 Therapeutics, Inc. | USD 3.58 | ▼ 7.01% |
| STTK | Shattuck Labs, Inc. | USD 4.27 | ▼ 6.77% |
| PRLD | Prelude Therapeutics Incorporat | USD 3.94 | ▲ 3.41% |
| FDMT | 4D Molecular Therapeutics, Inc. | USD 9.23 | ▲ 6.83% |
| ORIC | Oric Pharmaceuticals, Inc. | USD 8 | ▲ 6.67% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 01:00 UTC. This page is informational and not investment advice.